Altamira Therapeutics Reports Reduced Operating Loss; Finance Income Soars for H1 2025
Altamira Therapeutics Ltd. reported its financial results for H1 2025, showing an operating loss of $2.63 million, improved from $3.92 million in H1 2024. Other operating income rose to $80,951, while finance income surged to $1.66 million. R&D and administrative expenses decreased significantly. The company aims to secure $2.8 to $3.5 million in funding through various strategies, including a spin-off of its RNA delivery business. Cash and cash equivalents ended the period at a deficit of $10,839, down from a surplus of $65,455 in the previous year.
Altamira Therapeutics Ltd. released its condensed consolidated interim financial results for the six months ended June 30, 2025. The company reported other operating income of $80,951, a significant increase from $34,298 in the same period in 2024. However, the operating loss for the period was $2.63 million, an improvement compared to a loss of $3.92 million in the prior year. The research and development expenses decreased to $1.47 million from $1.96 million, while general and administrative expenses fell to $1.24 million from $1.99 million. Finance income notably rose to $1.66 million from $513. The company is exploring avenues for generating $2.8 to $3.5 million in funding within 12 months from the reporting date, primarily through the spin-off of its RNA delivery business and revenue from licensing, partnering activities, and potential grant funding. Cash and cash equivalents at the end of the period were recorded at a deficit of $10,839, compared to a surplus of $65,455 at the end of the corresponding period in 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-082071), on August 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
